Allogeneic haematopoietic SCT (HSCT) induces CRs in most patients with CML. With the excellent short-term treatment results induced by imatinib (IMA), attitudes have changed and only a minority of children are now transplanted upfront. This review addresses the role of IMA in children with CML, focusing on the starting dose of IMA, possible adverse effects, timing of HSCT in children, duration of IMA treatment and monitoring of treatment efficacy to unravel failure of early treatment of IMA as well as treatment of CML relapse after HSCT. As the paediatric experience with IMA is still very limited, many answers and algorithms are adapted from CML in adults. Basically, HSCT should be postponed to achieve an optimal tumour cell reduction by IMA treatment. Children with a low-risk EBMT score should undergo HSCT within 2 years after diagnosis to avoid prolonged exposure and unknown late effects of IMA. Without a perfectly HLA-matched donor, HSCT may be postponed until CML becomes refractory to IMA. As realized in the presently activated international trial CML-paed II, this approach represents a risk-adapted therapy with the benefit of being tailored to the needs and profile of an individual patient.
Introduction
Chronic myeloid leukaemia is characterized by a multi-step evolution with several defined stages (chronic phase (CP), accelerated phase (AP), blast crisis (BC)) and was the first malignancy found to be associated with a defined cytogenetic abnormality-the Ph chromosome. 1, 2 The elucidation of its molecular pathogenesis involve the BCR-ABL fusion transcripts, whose constitutive activation of the tyrosine kinase (TK) activity contributed by the Abl component resulted in successful development of imatinib mesylate (IMA) as a milestone of molecular targeted therapy approach. 3 IMA inhibits the activity of the BcrAbl fusion protein that appears to be the causative molecular alteration in CML. The recent development of second-generation TK inhibitors probably marks the preliminary end of 150 years of attempts to treat and cure CML. 4, 5 Any treatment resulting in reduction or elimination of the Ph-positive cells from the BM changes the natural history of CML. More than 25 years ago, allogeneic haematopoietic SCT (HSCT) provided proof of principle that the disease was cured by eradicating the malignant clone. Interferon-a (IFN) was the first immunomodulatory agent to offer a nontransplant intervention inducing any degree of Ph-negative metaphases. 6 Starting from 1983, IFN became the treatment of choice for patients not eligible for HSCT. Although the median survival time of CML in this 'pre-IMA' era was 5 years, complete cytogenetic responders to IFN were surviving more than a decade. 7 However, only a small proportion (5-10%) of patients turned out to respond to IFN. Therefore, until 2000, although the morbidity and mortality attributable to HSCT were appreciable, it was state of the art to offer HSCT to younger patients who had suitable HLA-matched donors. 8 During the last 8 years, as a result of targeted therapy with IMA, the role of allografting is changing and the frequency of HSCT in CML has been reduced dramatically.
Chronic myeloid leukaemia constitutes approximately 2-3% of all childhood leukaemias and only a few studies have specifically addressed CML in childhood. [9] [10] [11] [12] [13] Because of the rarity of the disease, this was mostly done retrospectively and data were pooled from different studies or pre-existing publications. It is agreed that for children undergoing HSCT, risk factors and outcome are comparable to those observed in younger adults. [14] [15] [16] This paper attempts to discuss how IMA can be moved safely into mainstream therapy in paediatric CML without compromising the excellent long-term cure rates achievable in children with HSCT from fully HLA-matched donors.
Imatinib
Imatinib has dramatically reduced the yearly risk of progression from CP to advanced stages to less than 1% per year. [17] [18] [19] [20] [21] [22] [23] However, it does not cure the disease and as in most-if not all-patients, leukaemic stem cells will persist. 4 Because of various biological mechanisms, resistance to IMA during treatment may develop. 22 Thus, until today HSCT remains the only proven option for cure in CML. Nevertheless, IMA must be currently considered as the best upfront treatment for CML, a benefit that should be offered also to children. 24 The efficacy and side effects of this new drug have been evaluated in paediatrics in controlled phase I and phase II trials comprising less than 100 patients so far. [25] [26] [27] The starting dose in children should be near 300 mg/m 2 (260-340 mg/m 2 were identified as giving drug exposures similar to the 400-600 mg adult dosage levels) orally once daily. The results from small paediatric phase II trials, similar to those in adults indicated that, in CP most patients achieve normal blood counts within 3 months and that complete haematological and cytogenetic responses are achieved with a probability of 96 and 69%, respectively, after one year of treatment. [25] [26] [27] The drug is licensed since 2003 for use in children, but long-term experience with IMA in children of all age groups is still very limited and the durability of responses as well as longterm side effects of this drug remains to be determined.
Adverse effects of IMA
Side effects including nausea, vomiting, diarrhoea, skin rash, elevated liver enzymes, oedema and cytopenias are observed in children in ratios similar to adults, especially when advanced stages of CML are treated. [25] [26] [27] The latter may be because of an inadequate reserve of normal stem cells, requiring treatment of neutropenia by G-CSF in some patients. Absorption and metabolism of IMA may be affected by other concomitant medications, and possible adverse effects of drug interactions must always be excluded first.
During the ongoing trials in adults with CML, about 10% of the patients developed chromosomal abnormalities in Ph-negative cells. These abnormalities, involving mostly chromosomes Y, 8 and 7, resemble chromosomal alterations typically present in myelodysplastic syndrome. 28 Their clinical consequence is unclear, as in most cases they are transient and appear to be less frequent in younger patients. 29 In an analysis including more than 500 patients, the overall prognosis for patients who had clonal aberrations and a Ph-negative status was good and was driven by the CML response to IMA. Therefore, at least in adults, isolated clonal aberrations in Ph-negative cells, in the absence of morphologic evidence of myelodysplastic syndrome, do not justify a change in therapy. 30 In children, it might be prudent to perform BM cytogenetic analysis at regular intervals as part of the monitoring under IMA treatment.
Congestive cardiac failure was described in 10 out of more than 1000 adults under treatment with IMA. 31 This so far unknown side effect could be reproduced in rodent animal models exhibiting specific abnormalities of cardiac mitochondria. However, analyses in a large number of patients showed that the incidence of cardiac failure in a larger cohort was not greater than what would be expected in previously healthy individuals of similar age. 32 IMA also exerts an influence on the bone metabolism by impairing the differentiation and activity of osteoblasts and osteoclasts. In adults, hypophosphataemia in association with decreased levels of calcium, 25-OH-vitamin D, and 1,25-OH-vitamin D has been described. [33] [34] [35] [36] These side effects may be of major concern in still growing patients.
Female teenagers must be advised to avoid conception while taking IMA, as the rate of fetal abnormalities in some unavoidable pregnancies was higher than expected in a comparable healthy population. 37 
Initial therapy in children with CML
In chronic phase of CML In a patient with CML the well-known risks of HSCTassociated if successful with the cure of leukaemia-have to be balanced against treatment with IMA that promises to prolong life without any definite prospect of cure including uncertainty on possible adverse late effects (Table 1) . Because CML is so rare in childhood, prospective trials have been difficult to organize. By comparing the few studies on paediatric CML and HSCT, however, one sees an outcome that is similar to younger adults in large multicentre trials with 60-75% survival. 38 The factors that affect outcome of HSCT are clearly defined by the EBMTrisk score, which also represents a reliable tool in paediatric transplantation. 39 The prospective trial CML-paed I, running from 1995 to 2004, aimed to transplant children with CML in first CP after treatment with hydroxyurea±IFN from an HLA-matched family donor within 6 months and those with an unrelated donor within 12 months after diagnosis. 15, 40 This approach resulted in an excellent probability of survival at 5 years of 87±11% (Figure 1 ) in the group grafted from HLA-identical family donors (n ¼ 41), but only 52 ± 9% if grafted from an HLAmatched unrelated donor (n ¼ 71) and 45±16% if grafted from an HLA-mismatched unrelated donor (n ¼ 36). The time interval from diagnosis to HSCT exerted a statistically insignificant influence on the outcome: the probability of survival for patients at 5 years transplanted HLA-fully matched in CP1 (n ¼ 144) was 74 ± 9%, if the procedure was performed within 6 months after diagnosis (n ¼ 49), and each 62±15% if performed after 6-12 months (n ¼ 52), or later than 12 months after diagnosis (n ¼ 43), Table 1 Risk-benefit considerations when balancing the use of short-term or long-term imatinib in childhood CML -Imatinib must currently be considered as the best upfront treatment for CML, a benefit that should be offered also to children.
-This benefit in initial treatment of CML for a limited period outweighs the risks of a still restricted experience with this drug in children.
-For the long-term treatment of CML with imatinib, the benefits cannot be balanced against the risks because of the lack of data for this drug in children.
-Treating children with CML by imatinib until the best response is achieved followed by Haematopoietic SCT from an optimal selected donor represents a risk-adapted therapy with the benefit of being tailored to the needs and profile of an individual patient.
respectively. 41 This trial was stopped 2004 because it was no longer recruiting patients after IMA had been fully licensed, and paediatricians in practice recommended this new drug as initial treatment. The same way as in adults, the annual number of HSCT performed for CML fell markedly long before the first clinical data on IMA in children were published. 42 For most physicians, a welltolerated pill with impressive short-term effects seemed to be more attractive than the complex treatment by HSCT with high initial and long-term risks.
The consecutive trial CML-paed II was started in 2007 as an approach to separate patients with high-risk disease (and a possible low-risk donor) who should undergo HSCT early from patients with low-risk disease and high-risk donors (not fully HLA-matched) in whom a prolonged trial with IMA might be favoured. Newly diagnosed Ph-positive CML will be treated upfront with IMA followed by serial monitoring of treatment response. Patients with IMA failure will proceed to HSCT (Figure 2 ). In adults, it was shown that earlier IMA treatment exerted no negative impact on the outcome of HSCT. 43 All responders to IMA treatment with an HLA-matched donor will undergo HSCT no later than 2 years after diagnosis. By this approach, it may be anticipated that long-term eradication of the disease may even be improved by lowering the post HSCT relapse rates through earlier tumour cell reduction by IMA. Statements balancing the arguments for and against this approach of the CML-paed II study are listed in Table 1 .
In advanced stages of CML Inferior prognosis has been reported for adults undergoing HSCT in AP or BC. Cwynarski et al.
14,44,45 reported a survival probability of 30% at 3 years for 61 out of 314 children (19%) transplanted in AP. Therefore, any attempts to achieve a second CP should be undertaken before transplantation. The general response to IMA for advanced stages of CML is of short duration. As shown in adults, treatment should be started in these children with higher doses of IMA (400 mg/m 2 (maximum absolute dose 600 mg) in AP, and 500 mg/m 2 (maximum absolute dose 800 mg) in BC, respectively). 44 Having achieved CP, they should proceed to HSCT as fast as possible. In BC not responding to IMA, induction chemotherapy from ALL or AML protocols can induce another CP. The probability of survival at 4 years for nine patients from trial CML-paed I transplanted in AP was 48±34%. This is clearly inferior to patients being transplanted in CP1, but it demonstrates that HSCT is not a hopeless treatment option for children with CML in AP. 46 
Monitoring treatment with imatinib
Although IMA response may vary considerably in individual patients, it proceeds in an orderly manner starting with normalization of blood cell counts and spleen size, followed by reduction of Ph-positive metaphases in the BM, and eventually with reduction of BCR-ABL transcripts to very low or even undetectable numbers. Therapeutic response in individual patients is therefore checked sequentially on the three levels of haematological, cytogenetic and molecular response. 21 Patients should be monitored closely to not miss IMA failure. In addition, the degree to which the disease burden is reduced, as judged by the number of Ph-positive metaphases and the BCR-ABL transcript numbers, correlates inversely with the probability of maintaining responsiveness to IMA. 48 On the assumption that this also holds true also for children with CML, definitions of failure or suboptimal response as established for adults were adopted for trial CML-paed II (Table 2) , with the difference that over a 2-year period, BM cytogenetics should be performed regularly at 3-month intervals to not miss the development of additional clonal chromosomal aberrations. 21 Concerning molecular monitoring, it must be stressed that the sensitivity level for detection of low numbers of BCR-ABL transcripts differs in different laboratories and that standardization of testing for quantitative reverse transcription-PCR is mandatory. 20 
How long should treatment with imatinib be continued?
This key question currently is easy to answer only for the group of paediatric patients experiencing IMA failure (either primarily or secondarily, see below). As in the past, HSCT should be recommended without any delay as long as the patient is in CP. If no donor or only donors with HLA-disparity (42 minor or major HLA mismatches, 10/10 alleles analysed by high resolution typing) are available, the child might be put on IFN±low dose cytarabine as the best evaluated treatment next to IMA. Notice should be taken of the upcoming results from trials in adults on second generation TK inhibitors; individual paediatric patients may be treated in upcoming and future controlled trials. 44 It is mandatory to rule out the T351I mutation (see Failure to imatimib treatment) before changing treatment to dasatinib or nilotinib.
The second group comprises children with an excellent response to IMA who have an HLA-fully matched donor. These patients should proceed to HSCT within 2 years from diagnosis keeping in mind that there is no experience in children so far on the long-term side effects of prolonged treatment with IMA, for example, on skeletal growth, especially in young children. Stopping IMA in the situation of undetectable BCR-ABL transcripts currently cannot be recommended. In a small series on adults published, this resulted in molecular relapse in 6 of 12 patients within 5 months, whereas the other half remained in molecular Table 2 Recommendations for definitions of failure to imatinib or suboptimal response to imatinib used in adults, which are also applicable in childhood CML Modified from recommendations and definitions used in adults with CML. 21, 44 As no information on the kinetics of response in children is available from larger series so far, monitoring beyond 6 months is performed in contrast to adults ongoing at 3-month intervals to not overlook additional chromosomal abnormalities in Ph-negative cells.
remission for a median of 15 months. 49 Evidently, this cohort is too small to delineate definite conclusions.
The third group comprises IMA responders without an acceptable donor available. In these children, IMA should be continued under regular monitoring for the BCR-ABL transcript number, the appearance of clonal cytogenetic aberrations and any side effect of the IMA treatment. There is preliminary evidence that the incidence of disease progression diminishes in responders with each successive year on IMA. 3 This risk is less than 1% per year in adults and cannot be balanced currently against the so far unknown late effects of prolonged IMA treatment in children. Figure 2 shows this algorithm, which of course has always to be reconsidered in the light of newly appearing data.
New TK inhibitors
To make counselling still more complicated, second generation TK inhibitors, active also against most of the IMA resistant subclones, such as dasatinib (300 fold more active than IMA), nilotinib (20-50 fold more active than IMA) and bosutinib, as well as aurora kinase inhibitors such as MK-0457, which is also active against the T351I mutation (dasatinib and nilotinib are not active against this mutation) show that resistance to IMA can be overcome. 44 These drugs are currently evaluated in clinical trials in adults, but with the exception of dasatinib (phase II) no controlled studies have been carried out so far in children.
Failure to imatinib treatment
The development of clinical resistance to IMA, either primary or secondary, constituted a major drawback in the treatment of CML. Primary resistance to IMA-defined as an inability to achieve landmark response-is comprised in adults treated with IMA upfront for CML in CP of the 2% of patients who fail to achieve haematological response and 8-13% who fail to achieve major or complete cytogenetic response. 3, 50, 51 Secondary resistance refers to patients initially responding but then losing this response. In the IRIS trial, this group comprised 18% of the patients after a median of 5 years. However, such events appeared to be most evident in the first 3 years where progression to advanced phases of CML averaged 2% per year, and progression within CP averaged 5% per year and then showed diminished rates for both risks to less than 1% in the fifth year. 3 Mechanisms for resistance may include individual variations in the pharmacokinetics of the drug (uptake of IMA into cells by human organic cation transporter; increased drug efflux caused by high Pglycoprotein levels) as well as mutations of the ATPbinding site of the BCR-ABL tyrosine kinase, BCR-ABL amplification at the genomic or transcript level, overexpression of other tyrosine kinases such as the SRCrelated LYN kinase, or clonal evolution with aberrant karyotypes leading to BC. Patients who fail IMA treatment should be screened for the presence of kinase domain mutations, especially for T351I. 22, 44 So far, no data specific for children with CML under IMA treatment have been established to define a patient as having failed IMA at the standard dose. In adults, a group of international experts proposed criteria and time points to define failure or suboptimal response (Table 2) , including category 'warnings' to identify patients responding less well. 21 Assuming that mechanism dictating the underlying resistance to IMA and the kinetics by which these develop are not different in childhood CML compared to adults, these criteria may also be applied in paediatrics.
Relapse of CML after HSCT
IMA may be used as a prophylaxis to prevent relapse or to eliminate residual disease after HSCT, especially in situations such as T-cell depletion where a high relapse rate is anticipated. However, this approach might be limited by selection of resistant cells and it must be kept in mind that IMA does not affect quiescent CML stem cells. Patients experiencing either molecular, cytogenetic or haematological relapse post HSCT are very effectively treated by donor lymphocyte infusions. 52 However, this approach might induce life-threatening GVHD. IMA may also induce another remission, but in most cases this is followed by another relapse once the drug is withdrawn. IMA should possibly be used first followed by the cautious use of lowdose donor lymphocyte infusions at intervals not less than 12 weeks. 53 
Conclusion
Imatinib is now licensed for treatment of CML in more than 80 countries of the world, but data on children are still scarce. In Europe (I-BFM-group) and in the USA (COG), carefully planned paediatric trials are integrating the combination of IMA as the best-investigated Ph-positive cell reducing agents currently available with the approach of definite cure by HSCT in a step-wise manner.
